Images List Premium Download Classic

Cardiovascular

Cardiovascular-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Lipoprotein analysis by differential charged-particle mobility
Quest Diagnostics Investments Incorporated
January 11, 2018 - N°20180011117

The invention provides methods of preparation of lipoproteins from a biological sample, including hdl, ldl, lp(a), idl, and vldl, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for ...
Lpl/rlp for assessment of cardiovascular disease risk
True Health Diagnostics, Llc
January 11, 2018 - N°20180011094

In various embodiments, the application relates to methods for assessment of cardiovascular disease (cvd) risk in a patient comprising comparing pre-heparin lpl (lipoprotein lipase) levels which are associated with protection from cvd to remnant lipoprotein cholesterol (rlp-c) and/or remnant lipoprotein triglyceride content (rlp-tg).
Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
The Regents Of The University Of California
January 11, 2018 - N°20180010148

In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, ...
Cardiovascular Patent Pack
Download 516+ patent application PDFs
Cardiovascular Patent Applications
Download 516+ Cardiovascular-related PDFs
For professional research & prior art discovery
inventor
  • 516+ full patent PDF documents of Cardiovascular-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
University Of Zurich
January 11, 2018 - N°20180009907

Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for fibroblast activation protein (fap) expression in a body fluid is provided as well as therapeutic means based thereon.
Heterocyclic compounds as pi3k-y inhibitors
University Of Zurich
January 11, 2018 - N°20180009816

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Inhibitors of the renal outer medullary potassium channel
Merck Sharp & Dohme Corp.
January 11, 2018 - N°20180009807

The present invention provides compounds of formula i (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1. 1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive ...
Cardiovascular Patent Pack
Download 516+ patent application PDFs
Cardiovascular Patent Applications
Download 516+ Cardiovascular-related PDFs
For professional research & prior art discovery
inventor
  • 516+ full patent PDF documents of Cardiovascular-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Health care
Cardiorentis Ag
January 11, 2018 - N°20180008618

The treatment of type 2 diabetes involving the use of a regimen comprising: (a) one or more glucose-lowering drugs (g-lds) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (b) at least one non-steroidal anti-inflammatory drug (nsaid) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “mg salicylate”); (2) naproxen; and (3) ...
Novel uses
Intra-cellular Therapies, Inc.
January 04, 2018 - N°20180000825

The invention relates to the administration of inhibitors of phosphodiesterase 1 (pde1) for the treatment of diseases or disorders characterized by disruption of or damage to various cgmp/pkg mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (pde1) for treatment of cardiovascular disease and related disorders, e. G., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa ...
Dezima Pharma B.v.
January 04, 2018 - N°20180000818

The present invention relates to a pharmaceutical composition and a therapeutic combination comprising a novel cholesteryl ester transfer protein (cetp) inhibitor and a hmg coa reductase inhibitor, which may be used in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia.
Cyclic ureas as inhibitors of rock
Bristol-myers Squibb Company
January 04, 2018 - N°20180000788

The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Compositions and methods for treating cardiovascular diseases
Infirst Healthcare Limited
January 04, 2018 - N°20180000763

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
Assessing cardiovascular function using an optical sensor
Google Inc.
January 04, 2018 - N°20180000355

This document describes assessing cardiovascular function using an optical sensor, such as through sensing relevant hemodynamics understood by pulse transit times, blood pressures, pulse-wave velocities, and, in more breadth, ballistocardiograms and pressure-volume loops. The techniques disclosed in this document use various optical sensors to sense hemodynamics, such as skin color and skin and other organ displacement. These optical sensors require ...
Assessing cardiovascular function using an optical sensor
Google Inc.
January 04, 2018 - N°20180000354

This document describes assessing cardiovascular function using an optical sensor, such as through sensing relevant hemodynamics understood by pulse transit times, blood pressures, pulse-wave velocities, and, in more breadth, ballistocardiograms and pressure-volume loops. The techniques disclosed in this document use various optical sensors to sense hemodynamics, such as skin color and skin and other organ displacement. These optical sensors require ...
Cardiovascular Patent Pack
Download 516+ patent application PDFs
Cardiovascular Patent Applications
Download 516+ Cardiovascular-related PDFs
For professional research & prior art discovery
inventor
  • 516+ full patent PDF documents of Cardiovascular-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
Deuterx, Llc
December 28, 2017 - N°20170369420

The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
Tri-power exercising device
Deuterx, Llc
December 28, 2017 - N°20170368409

Tri-power exercising device allows a rider to simultaneously, or on demand, exercise virtually all muscle groups in his lower and upper body. The device includes a bicycle frame, pedals, forearm bars, sliding seat, computer and electronic display recommending energy modulation amounts from various muscle groups to optimize physical performance on any given trek. Because riders can exercise virtually all muscle ...
Battle rope strength trainer
Deuterx, Llc
December 28, 2017 - N°20170368405

In some embodiments, a battle rope strength trainer device is provided. The battle rope strength trainer device provides a multifunction exercise device that combines strength building properties of body weight strength exercises with the cardiovascular training of battle rope oscillation exercises in one product. In one embodiment, the battle rope strength trainer device includes an anchor, a rope and a ...
Polymer microbubbles as x-ray dark field contrast agents
University Of Pittsburgh - Of Higher Education
December 28, 2017 - N°20170368204

The present invention discloses compositions and methods for clinical imaging. In particular, these compositions and methods provide improvements to cardiovascular imaging. Such improvements are drawn to the creation and use of polymer-based microbubbles comprising metal nanoparticle additives that provide contrast images of highly improve resolution when compared to conventional lipid based microbubbles. For example, the compositions and methods may be ...
Cyclodextrin-based polymers for therapeutic delivery
Cerulean Pharma Inc.
December 28, 2017 - N°20170368194

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of a disease or disorder, e. G., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates.
Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
Siemens Healthcare Diagnostics Inc.
December 28, 2017 - N°20170368171

The invention provides human adipor2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The ...
Crystal forms of scutellarin aglycone and preparation thereof
Hlk Pharmaceuticals Co., Ltd.
December 28, 2017 - N°20170368019

The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The ...
Method for reversing, preventing, delaying or stabilizing soft tissue calcification
Panion & Bf Biotech, Inc.
December 28, 2017 - N°20170368016

The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in ...
Loading